 Cytochrome P-450 CYP2C9
"Cytochrome P-450 CYP2C9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.
| Descriptor ID |
D065729
|
| MeSH Number(s) |
D08.244.453.491.500.500 D08.811.682.690.708.170.450.500.500 D12.776.422.220.453.491.500.500
|
| Concept/Terms |
Cytochrome P-450 CYP2C9- Cytochrome P-450 CYP2C9
- CYP2C9, Cytochrome P-450
- Cytochrome P 450 CYP2C9
- P-450 CYP2C9, Cytochrome
- Cytochrome P450 PB-1
- Cytochrome P450 PB 1
- P450 PB-1, Cytochrome
- PB-1, Cytochrome P450
- Cytochrome P450 MP-4
- Cytochrome P450 MP 4
- MP-4, Cytochrome P450
- P450 MP-4, Cytochrome
- Cytochrome P450 MP-8
- Cytochrome P450 MP 8
- MP-8, Cytochrome P450
- P450 MP-8, Cytochrome
- CYP2C9
- CYPIIC9
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C9".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C9".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C9" by people in this website by year, and whether "Cytochrome P-450 CYP2C9" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C9" by people in Profiles.
-
Lazorwitz A, Aquilante CL, Sheeder J, Teal S. Letter to the Editor in Response to "Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally". Adv Ther. 2020 02; 37(2):963-964.
-
Quinn AL, Liko I, Lee JC. Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement. Pharmacogenomics. 2017 Jul; 18(11):1051-1057.
-
Wiley LK, Vanhouten JP, Samuels DC, Aldrich MC, Roden DM, Peterson JF, Denny JC. STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. Pac Symp Biocomput. 2017; 22:545-556.
-
Floyd JS, Sitlani CM, Avery CL, Noordam R, Li X, Smith AV, Gogarten SM, Li J, Broer L, Evans DS, Trompet S, Brody JA, Stewart JD, Eicher JD, Seyerle AA, Roach J, Lange LA, Lin HJ, Kors JA, Harris TB, Li-Gao R, Sattar N, Cummings SR, Wiggins KL, Napier MD, St?rmer T, Bis JC, Kerr KF, Uitterlinden AG, Taylor KD, Stott DJ, de Mutsert R, Launer LJ, Busch EL, M?ndez-Gir?ldez R, Sotoodehnia N, Soliman EZ, Li Y, Duan Q, Rosendaal FR, Slagboom PE, Wilhelmsen KC, Reiner AP, Chen YD, Heckbert SR, Kaplan RC, Rice KM, Jukema JW, Johnson AD, Liu Y, Mook-Kanamori DO, Gudnason V, Wilson JG, Rotter JI, Laurie CC, Psaty BM, Whitsel EA, Cupples LA, Stricker BH. Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J. 2018 01; 18(1):127-135.
-
Jonas DE, Evans JP, McLeod HL, Brode S, Lange LA, Young ML, Shilliday BB, Bardsley MM, Swinton-Jenkins NJ, Weck KE. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013 Oct; 14(13):1593-603.
-
Sy-Cordero AA, Graf TN, Runyon SP, Wani MC, Kroll DJ, Agarwal R, Brantley SJ, Paine MF, Polyak SJ, Oberlies NH. Enhanced bioactivity of silybin B methylation products. Bioorg Med Chem. 2013 Feb 01; 21(3):742-7.
-
Barry EL, Poole EM, Baron JA, Makar KW, Mott LA, Sandler RS, Ahnen DJ, Bresalier RS, McKeown-Eyssen GE, Ulrich CM. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. Cancer Causes Control. 2013 Jan; 24(1):47-54.
-
Brunt VE, Minson CT. KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin. J Physiol. 2012 Aug 01; 590(15):3523-34.
-
Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost. 2012 Feb; 107(2):232-40.
-
Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):359-72.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|